Our @iCardioAlliance Global Implementation Guidelines for the Management of #Obesity 2025 now in Global Cardiology Lead by Dr. Anker with global experts to create international guidelines on obesity management @fjpinto1960 @ShelleyZieroth @DBelardoMD @SubodhVermaMD

Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program DOI: 10.1016/j.jchf.2025.102610 Contributed by Baim faculty: @ambarish4786 & @JavedButler1 👏👏 #Obesity #Cardiology

Happy Heart Day from the Operating Room! ⁦@DLBHATTMD⁩ ⁦@hmkyale⁩ ⁦@GilbertTangMD⁩ ⁦@BobbyYanagawa⁩ ⁦@JavedButler1⁩

On #WorldHeartDay, we’re highlighting our commitment to treating #cardiovascular (CV) diseases. Learn more about our clinical trial in patients with #obesity and CV risk, and how our targeted approach is re-imagining how these diseases are treated: https://t.co/j6PJ0dwxLE

Last day of HFSA Scientific Sessions — and we couldn’t be prouder of our HFC members! What a successful year for the heart failure community and our team 💙 Check out the final day’s agenda, and congratulations to everyone involved in driving progress in heart failure care!

RT @dranulala: Happening now!! JCF DEBATES!!!! 101 J All ⭐️⭐️⭐️ speakers and 🔥🔥🔥 topics!

Join this @HFSA dinner symposium on #device therapies in #HF across #LVEF What’s old (& has withstood the test of time & trials) And what’s new (& in the evidence pipeline) Chaired by @JavedButler1 Fri, Sept 26th 8 pm CST Grand Ballroom F Hilton Minneapolis #HFSA25

Just released in @JCardFail - the @HFSA HF Stats 2025 report! 📖 Read the report ➡️ https://t.co/z0cObHYV3M… 📺 Watch the highlights ➡️ https://t.co/5Xqth9vH33 🎯 Make these data count 👏 Special thanks to the entire writing group #HFStats2025 #heartfailurestats

Wow, HF Prevention Makes Front Page of @TheLancet! Watershed moment to prioritize early screening, diagnosis, & treatment of HF 🔍 Identify Stage B “pre-HF” 💻 Quantify risk 🩺 Address modifiable RFs 👩🏽‍⚕️ Implement #CKM therapies 🫱🏾‍🫲🏽 Collaborative care https://t.co/4fqdyVSp86

We wrap up another Fall 2025 HFC Think Tank Meeting session with incredible discussions focused on site-based research Thanks to all those who attended and contributed to shaping the future of the field! #HFC #ThinkTankSeason

Glomerular filtration rate (GFR) is more than a biomarker! yes, it’s playful & dances in response to therapies but it is a direct reflection of kidney function its decline is a necessary intermediate to kidney failure thus is considered by regulators as an acceptable endpoint

Time to keep score of quadruple GDMT in HFrEF 1.2 million lives at stake each year

The Free, Open Source, Copyleft Textbook https://t.co/6YDLJFl0Rv edited by Thousands of Doctors Millions of times that I founded in 2006 had 85.9 Million page views last month with an annualized rate over 1 billion views per year https://t.co/6YDLJFl0Rv !

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced In HFrEF, AF did not significantly modify outcomes after adjustment and did not associate with eGFR

Excellent review @JavedButler1 impress about our HFpEF phenotypes, role of inflammation and obesity @hfcollaboratory #inflammation

@hfcollaboratory @escardio @JavedButler1 @coconnormd @mfiuzat @ESC_Journals @ESCardioNews @mvaduganathan @SJGreene_md The systematic review by @JavedButler1 addresses a significant aspect of heart failure treatments by focusing on HFpEF phenotypes, which could pave the way for more personalized therapeutic approaches. As we continue to see advancements in medical devices for heart failure,

New in @escardio a systematic review led by #HFC member @JavedButler1 explores emerging medical device and surgical interventions for treating HFpEF and proposes specific HFpEF phenotypes to guide future targeted therapies. #HeartFailure #HFpEF https://t.co/YOWcKTl6KQ

Our state-of-the-art review on moderate secondary MR in HF now publ in JACC. Like severe MR, mod SMR has been linked to death and HF hosp, but there are no guideline indications for any Rx. Is it time for M-TEER? RESHAPE-HF2 says "maybe". A dedicated RCT is necessary.

🟥 Une étude publiée par les docteurs @AmberTangMD, Boback Ziaeian et @JavedButler1 démontre que l’application optimale du traitement médical quadruple guidé par les recommandations (TMGD) en cas d’insuffisance cardiaque pourrait sauver près de 1,19 million de vies par an dans le

Outpatient Worsening HF (Oral Diuretic Intensification) ☑️ Frequent ☑️ Prognostically meaningful ☑️ Temporally precedes 🏥 ☑️ Similar treatment effect sizes #GDMT as those on 🏥 Building evidence for its role in broader composite esp in lower-risk CKM pts https://t.co/pJPiy2b7u7